Loading…
Develops cancer therapies targeting genetic vulnerabilities discovered through large-scale CRISPR tumor screens.
Develops cancer therapies targeting genetic vulnerabilities discovered through large-scale CRISPR tumor screens.
Has no approved product and so no sales; spending is funded by money raised from investors and by payments under partnerships with larger drug makers. Each clinical readout on its lead programs shapes both the funding it can raise and the value of any partnership.
Moat: none (IP / patents, data). Proprietary CRISPR-based target discovery platform but still clinical-stage with no approved drugs.
Headquarters: Boston, Massachusetts, US · Founded: 2017 · Employees: 137
Size Tango Therapeutics (TNGX) is a United States Health Care company (Biotechnology) with a market value of $3.63B, the 1410th largest of 3,117 United States companies the cockpit tracks. Shares closed at $21.50 on 6 Nov 2026.
Performance Over six months the shares fell 6.6%, against +7.3% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 121.5% over the last twelve months (peer median +5.4%); the operating margin is -253.4% (peer median -35.3%).
Valuation It trades at 49.1× enterprise value to sales against a peer median of 12.6× (5th most expensive of 17).
Short interest Short interest is 26.6% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $53.8M | $62.4M | $42.1M | $36.5M | $24.9M |
| Revenue growth | — | +48% | +15% | +47% | — |
| Gross profit | $51.9M | $60.1M | $39.6M | $34.1M | $20.8M |
| EBITDA | -$134M | -$109M | -$143M | -$112M | -$107M |
| Net income | -$124M | -$102M | -$130M | -$102M | -$108M |
| Free cash flow | -$144M | -$140M | -$132M | -$120M | -$117M |
| Capital expenditure | $373,000 | $1.05M | $754,000 | $1.53M | $7.69M |
| Total debt | $32.0M | $33.6M | $36.5M | $38.9M | $41.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tango Therapeutics TNGX | $3.63B | -7% | +121% | -253% | 49.1× | n/a |
| IDEAYA Biosciences IDYA | $3.02B | +10% | -83% | -1,267% | 60.5× | n/a |
| Revolution Medicines RVMD | $41.2B | +36% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TNGX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.7% | +2.9% | 9th lowest of 21 |
| 6-month return | -6.6% | +7.3% | 7th lowest of 21 |
| Distance from 52-week high | -37.5% | -24.0% | 5th lowest of 21 |
| Revenue growth (TTM) | +121.5% | +5.4% | highest of 16 |
| Operating margin | -253.4% | -35.3% | 5th lowest of 17 |
| EV / Sales | 49.1× | 12.6× | 5th most expensive of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $4.43B | +9% | +17% | -4% | 15.1× | n/a | n/a |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |